Booming Irish pharmaceutical sector sets sights on China
Updated: 2013-05-27 10:15
(Xinhua)
|
||||||||
"It's a very important relationship and it's developing more and more significance as each day goes by. So we liaise a lot with our Chinese partners both from a research but particularly from a training and education perspective," said O'Driscoll.
While Ireland is a relatively small country, its dedication to research and development along with its educated workforce makes it tailor fit to the production of pharmaceuticals.
"We have a very strong regulatory framework which companies really appreciate because it gives them a lot of guidance and security in terms of what they are achieving and the industry has really been able to access excellent talent here with the engineering and science graduate output from the universities. They've had, I think, a second to none track record in excellence in both development and manufacturing," Heavey said.
O'Driscoll said it's a key component to develop the industry in Ireland. "It's an industry based on science and technology so all the new products are very much based on research and development so having a strong internationally focused R&D sector is a critical component," he said.
Heavey said there's been a big focus as part of government efforts to prioritize the investment of the 8 billion euros ($10.3 billion) in research funding.
"One of the areas that's been identified as an area for focus from the stakeholder group is in research and development that supports manufacturing of therapeutics and process development," he said.
In Ireland, pharmaceutical and bioprocessing industries have been growing very strongly in the last number of years. Ireland is now the No 1 location in Europe for life sciences foreign direct investment.
"Over 50 percent of our gross domestic product is driven by life sciences and within that we've seen a number of very strong investments from companies such as Amgen, Merck and Lilly over the last 12 to 24 months," said O'Driscoll.
Laurent Borla, general manager of Arkopharma Ireland, listed several key reasons for the French-based multinational decided to invest in Ireland.
"Ireland was chosen because it's an English speaking country, it's in the eurozone, there is a well educated workforce, the climate is quite proper to control environments, it's never too warm, never too cold so there is good savings to be made on energy costs and it's just a great place to be in. I mean, the quality of life in Ireland is quite spectacular and it's important when people work hard, after a long day," said Borla.
- Ireland eyes stronger economic ties with China
- Ireland's credit rating reduced
- Executives call for pharmaceutical reform
- China orders chemical pharmaceutical exports survey
- Pharmaceutical market to hit 2.3t yuan by '20
- Alliance Boots buys stake in Nanjing Pharmaceutical
- China beefs up pharmaceutical regulation
- Michelle lays roses at site along Berlin Wall
- Historic space lecture in Tiangong-1 commences
- 'Sopranos' Star James Gandolfini dead at 51
- UN: Number of refugees hits 18-year high
- Slide: Jet exercises from aircraft carrier
- Talks establish fishery hotline
- Foreign buyers eye Chinese drones
- UN chief hails China's peacekeepers
Most Viewed
Editor's Picks
Pumping up power of consumption |
From China with love and care |
From the classroom to the boardroom |
Schools open overseas campus |
Domestic power of new energy |
Clearing the air |
Today's Top News
Shenzhou X astronaut gives lecture today
US told to reassess duties on Chinese paper
Chinese seek greater share of satellite market
Russia rejects Obama's nuke cut proposal
US immigration bill sees Senate breakthrough
Brazilian cities revoke fare hikes
Moody's warns on China's local govt debt
Air quality in major cities drops in May
US Weekly
Geared to go |
The place to be |